| 4.04 0.04 (1%) | 11-11 15:51 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 41.44  |
1-year : | 64.23 |
| Resists | First : | 35.47 |
Second : | 55 |
| Pivot price | 6.45 |
|||
| Supports | First : | 3.9 |
Second : | 3.24 |
| MAs | MA(5) : | 4.53 |
MA(20) : | 10.31 |
| MA(100) : | 11.13 |
MA(250) : | 21.26 |
|
| MACD | MACD : | -2.3 |
Signal : | -1.8 |
| %K %D | K(14,3) : | 0.6  |
D(3) : | 0.9 |
| RSI | RSI(14): 40.1 |
|||
| 52-week | High : | 117.5 | Low : | 3.9 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GNPX ] has closed above bottom band by 20.8%. Bollinger Bands are 14.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.33 - 4.37 | 4.37 - 4.39 |
| Low: | 3.84 - 3.87 | 3.87 - 3.9 |
| Close: | 3.95 - 4.01 | 4.01 - 4.05 |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Tue, 04 Nov 2025
Genprex (NASDAQ: GNPX) gets EPO intent to grant patent for REQORSA+PD-1 in cancer - Stock Titan
Thu, 23 Oct 2025
Genprex’s gene therapy shows promise for ALK-positive lung cancer - Investing.com
Thu, 23 Oct 2025
Genprex (NASDAQ: GNPX) expects $2.7M upfront; up to $5.4M more from short-term warrants - Stock Titan
Thu, 23 Oct 2025
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules - PR Newswire
Tue, 21 Oct 2025
Genprex Executes One-for-Fifty Reverse Stock Split - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 83 (K) |
| EPS | 42.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -207.5 % |
| Return on Equity (ttm) | -612.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -17.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | 0.09 |
| PEG Ratio | 0 |
| Price to Book value | 1.88 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|